Hyperfine, Inc.

NASDAQ:HYPR

Medical - Devices

Healthcare
$0.56 +15.65%

+$0.22 today

Market cap
$51.10M
Beta
1.38
P/E (TTM)
-4.5
EPS (TTM)
-$0.36
52W Low $0.66High $2.22

Volume 1.16M

Average 0.60M

HYPR Pre-Tax Margin

Income before tax as a percentage of revenue.

Hyperfine, Inc.NASDAQ: HYPR

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -220.9%

Pre-tax margin was -220.9% in Q1 FY2026, up 219.8 pp from a year earlier. On a trailing-twelve-month basis it was -226.9%, up 116.5 pp year over year. Over 3 fiscal years it widened by 811.4 pp.

Context

  • Pre-tax margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-220.9%-109.2 pp QoQ
Last fiscal yearDec 2025
-262.3%+53.6 pp YoY
LTMMar 2026
-226.9%+116.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+219.8 pp——
1 year+53.6 pp——
3 years+811.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-262.3%
Year-over-year change
+53.6pp

Pre-Tax Margin vs competitors

How HYPR compares with its peers on the latest reported figures

  • HYPR's LTM Mar 2026 pre-tax margin of -226.9% is the 4th highest of the 6 companies compared; the peer median is -62.7%.
  • Its year-over-year change of +116.5 pp is the highest of 6, against a peer median of -3.0 pp.
  • Over three fiscal years its change of +811.4 pp compares with a peer median of -0.3 pp.
HYPR Competitors Peer median
Pre-Tax Margin for HYPR and competitors
Company Period LTM level YoY 3-year change
FONRFONAR CorporationLTM Mar 202610.8% -3.0 pp-10.1 pp
LUNGPulmonx CorporationLTM Mar 2026-59.4% +5.4 pp+50.2 pp
RCELAVITA Medical, Inc.LTM Mar 2026-62.7% +16.9 pp+9.5 pp
HYPRHyperfine, Inc.LTM Mar 2026-226.9% +116.5 pp+811.4 pp
IMAImageneBio IncFY2025-5712.4% -4667.9 pp-5272.1 pp
CNTBConnect Biopharma Holdings LimitedFY2025-86379.7% -86320.5 pp—
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding HYPR) -62.7%-3.0 pp-0.3 pp

Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.5M6.81M11.03M12.89M13.56M
Cost of Revenue2.66M5.91M6.28M7M6.81M
Gross Profit(1.17M)907K4.76M5.89M6.75M
Gross Margin-78.0%13.3%43.1%45.7%49.8%
Research & Development25.84M28.16M22.49M22.5M17.45M
Selling, General & Admin37.86M46.63M30.38M26.62M26.39M
Operating Expenses63.7M74.78M52.87M49.12M43.84M
Depreciation & Amortization726K1.02M1.05M1.01M2.2M
EBITDA(64.13M)(72.15M)(43.18M)(39.71M)(33.37M)
EBITDA Margin-4286.4%-1058.8%-391.4%-308.1%-246.1%
Operating Income(64.87M)(73.87M)(48.12M)(43.22M)(37.09M)
Operating Margin-4336.1%-1084.2%-436.1%-335.3%-273.4%
Interest Income18K761K3.84M2.49M1.02M
Interest Expense00000
Other Income / Expenses17K710K3.88M2.5M1.51M
Income Before Tax(64.85M)(73.16M)(44.24M)(40.72M)(35.57M)
Pre-Tax Margin-4335.0%-1073.7%-401.0%-315.9%-262.3%
Income Tax Expense00000
Net Income(64.83M)(73.16M)(44.24M)(40.72M)(35.57M)
Net Margin-4333.8%-1073.7%-401.0%-315.9%-262.3%
EPS (Basic)(0.92)(1.04)(0.62)(0.56)(0.43)
EPS (Diluted)(0.92)(1.04)(0.62)(0.56)(0.43)
Weighted Avg Shares70.33M70.45M71.32M72.41M94.2M
Weighted Avg Shares (Diluted)70.33M70.45M71.32M72.41M94.2M

Hyperfine, Inc.

NASDAQ:HYPR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.